HOOKIPA Pharma Inc. - HOOK STOCK NEWS

HOOKIPA Pharma (NASDAQ: HOOK) announced significant pre-clinical data showcasing their innovative 2-vector system for cancer treatment in the journal Cell Reports Medicine. This method demonstrated tumor-specific responses exceeding 50% of circulating CD8 T cells, resulting in tumor cures and long-term immunity. The alternating administration of arenaviral vectors showed no vector-neutralizing antibodies, indicating the possibility of repeated treatments. HOOKIPA is evaluating this technology in an ongoing Phase 1/2 clinical trial for HPV16+ cancers, with promising interim results expected by mid-2021.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The presentation will be available starting March 09, 2021, at 7:00 AM ET via a webcast on HOOKIPA's official website. The company is focused on developing immunotherapeutics using its proprietary arenavirus platform, targeting cancers and infectious diseases. Notably, their product candidates, HB-201 and HB-202, are in Phase 1/2 trials for HPV-positive cancers, while HB-101 is in a Phase 2 trial for kidney transplant patients.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Leerink Global Healthcare Conference on February 25, 2021, with a fireside discussion scheduled for 9:20 AM ET. This event will be accessible via a live audio webcast on HOOKIPA's website, alongside an archived replay available for 30 days post-event. HOOKIPA is advancing a new class of immunotherapeutics through its proprietary arenavirus platform, focusing on treatments for cancers and infectious diseases, including a Phase 1/2 trial for HPV-positive cancers and a Phase 2 trial for a cytomegalovirus vaccine.

HOOKIPA Pharma announced the closing of its underwritten public offering, raising approximately $80.9 million through the sale of 3,910,000 shares of common stock at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each. The preferred shares are convertible into 1,000 common shares. The offering was managed by Morgan Stanley and SVB Leerink, with RBC Capital Markets as lead manager. Proceeds will likely support HOOKIPA's development of immunotherapeutics targeting infectious diseases and cancers.

HOOKIPA Pharma has announced a public offering of 3,400,000 shares of common stock priced at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each, aiming to raise approximately $75 million. The offering is set to close on December 11, 2020. The underwriters have an option to purchase an additional 510,000 shares. The funds are intended for advancing its proprietary arenavirus platform targeting infectious diseases and cancers. This offering is made under a shelf registration statement with the SEC.

HOOKIPA Pharma announced an underwritten public offering of its common stock and Series A convertible preferred stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the offered shares. The offering is subject to market conditions, with no assurance regarding its completion or terms. Morgan Stanley and SVB Leerink serve as joint book-running managers. HOOKIPA is a clinical-stage biopharmaceutical company focused on immunotherapeutics targeting infectious diseases and cancers through its proprietary arenavirus platform.

HOOKIPA Pharma announced interim Phase 1 data for HB-201, a replicating monotherapy targeting HPV16-positive cancers. In a trial with 22 enrolled patients, 15 were evaluable, showing an 18% unconfirmed response rate in head and neck cancer patients who had previously received PD1 inhibitors. The treatment demonstrated a 73% disease control rate. Median progression-free survival is currently 72 days. Safety data indicated that 41% experienced treatment-related adverse events, primarily mild. HOOKIPA plans to explore further combination therapies.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported promising interim data for its CMV vaccine candidate HB-101, showing a 48% reduction in CMV viremia and no CMV disease in vaccinated kidney transplant recipients. The Phase 2 trial demonstrated a positive safety profile with a low incidence of side effects. Among the 41 participants, those receiving three doses had significantly better outcomes compared to the placebo group. The company is optimistic about progressing toward a Phase 3 trial, highlighting the vaccine's potential to address a critical unmet need in transplant care.

HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported its Q3 2020 financial results, revealing revenue of $4.0 million, up from $2.0 million in Q3 2019, primarily due to higher collaborations with Gilead. However, R&D expenses increased to $16.0 million from $11.0 million, contributing to a net loss of $13.6 million, compared to $11.4 million in the prior year. The company continues its clinical development, including the HB-201 and HB-202 oncology candidates, and is optimistic about upcoming efficacy data.